HOME >> MEDICINE >> NEWS
Heart valve ring reverses damage from congestive heart failure, easing symptoms

SAN FRANCISCO -- A new heart valve ring appears to help congestive heart failure patients regain lost heart function, reversing the disease's effects on heart structure in two ways and easing their disabling symptoms, researchers reported here today at the 85th Annual Meeting of the American Association for Thoracic Surgery.

A prospective study of the first 25 patients who had surgery to install the ring shows that it reduced the leakage of blood back through the mitral valve, which leads to the heart's main pumping chamber. But it also changed the shape of that chamber, called the left ventricle, helping its muscular walls contract and pump blood better.

All 25 patients had mitral valve regurgitation (leakage) as a result of distorted left ventricles, and were experiencing severe symptoms, before having surgery to install the ring. All experienced great improvement in their symptoms, and lived at least a month after the operation. All but two were still alive six months after surgery.

The ring was co-invented by Steven Bolling, M.D., the University of Michigan Cardiovascular Center cardiac surgeon who presented the results on behalf of the research team, and by Italian cardiac surgeon Ottavio Alfieri of the St. Raffaele Hospital in Milan. The ring is made of titanium and silicone rubber.

The technology was licensed to Edwards Lifesciences Corporation for development and commercialization, and will be marketed as the GeoForm mitral valve repair ring. Both the co-inventors and the U-M stand to benefit financially from the device's sale.

The GeoForm ring has been approved by the U.S. Food and Drug Administration for use in tightening leaky mitral valves. But the new data are the first indication that it also re-shapes the left ventricle, which often becomes distended and misshapen after a heart attack or infection attacks the heart muscle. Nearly 5 million Americans have congestive heart failure, and the number is expected to
'"/>

Contact: Kara Gavin or Sally Pobojewski
kegavin@umich.edu
734-764-2220
University of Michigan Health System
13-Apr-2005


Page: 1 2 3 4

Related medicine news :

1. Drug-eluting stent controversy explored in the American Heart Hospital Journal
2. Heart-failure patients benefit from pharmacist care
3. Study offers clues to Broken Heart Syndrome
4. Heart Failure 2007
5. Heart failure medication does not improve survival, compared to more widely used medication
6. UCLA neurologist honored with American Heart Associations Stroke Council Award
7. Heart failure: Mayo Clinic reveals abnormality in filling of the heart is frequent culprit
8. Heart catheters do not benefit patients
9. Heart Rhythm Society publishes final recommendations for heart patients
10. Heartburn drug may help to slow progression of chronic heart failure
11. Heart failure drugs may be beneficial for patients with hardening of the arteries

Post Your Comments:
(Date:6/19/2013)... Salt Lake City, UT (PRWEB) June 19, 2013 ... wellness companies : , In July 2013, Orriant ... optimize their participation rates, and maintain compliance with ... implemented allowing employees to receive wellness incentives if ... Orriant has announced they have been compliant with ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 As ... cancer continue to mount in courts throughout the U.S., ... Drug Administration (FDA) recently held a meeting to discuss ... as incretin mimetics. According to a June 12th ... from the makers of Januvia and similar drugs, following ...
(Date:6/19/2013)... In what is believed to be the largest follow-up ... hereditary dystonia a movement disorder that can cause ... report good success rates and lasting benefits. , Michele ... at Cedars-Sinai Medical Center,s Department of Neurology, and Ron ... at Beth Israel Deaconess Medical Center in Boston, published ...
(Date:6/19/2013)... disparities between minority and white clients in success ... these disparities vary widely from state to state. ... states there,s something amiss," says Stephan Arndt, Ph.D., ... strong racial and ethnic disparities for people in ... successfully, and those disparities are something we need ...
(Date:6/19/2013)... The Movement Disorders Center ... urologists with specialists in physical therapy, occupational therapy ... and their family members to manage diseases and ... also have the opportunity to participate in the ... disorders can be relentlessly progressive and disabling conditions, ...
Breaking Medicine News(10 mins):Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 2Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 3Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 2Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 3Health News:Long-term study reports deep brain stimulation effective for most common hereditary dystonia 2Health News:States vary widely on success rates for minorities in drug treatment programs 2Health News:States vary widely on success rates for minorities in drug treatment programs 3Health News:Abington Memorial Hospital’s Neurosciences Institute Opens Movement Disorders Center 2
(Date:6/19/2013)... MUMBAI, India , June 19, ... Book Bureau has recently added DrugPatentWatch ... Databases. ( http://www.bharatbook.com/drugpatentwatch-tour.pdf ) ... DrugPatentWatch provides comprehensive information on pharmaceutical, ... value-added information supports the critical business ...
(Date:6/19/2013)... --  Nektar Therapeutics (Nasdaq: NKTR ) today ... study for NKTR-181, a first-in-class, opioid analgesic molecule ... slow rate of entry is designed to reduce the euphoria ... current opioid analgesics. 1 In the study data being ... in "drug liking" and "feeling high" scores and had highly ...
(Date:6/19/2013)... June 19, 2013 BD Biosciences, a segment of ... a leading global medical technology company, today announced the launch ... latest in its line of high-performance research flow cytometers. ... multicolor analysis with the most compact footprint in its class ... a height of 30" (76.2 cm). Recognizing that space is ...
Breaking Medicine Technology:Drug Patent Watch 2Drug Patent Watch 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 4Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 5Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 6Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 7Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 8Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 9New BD Biosciences Flow Cytometry Cell Analyzer Enables Complex Multicolor Experiments in Disease Research 2
Cached News: